Home ▸ About us ▸ Governance ▸ Board of Directors

Board of Directors

Governance
General Meetings
Board of Directors
Leadership Team
Committees
Auditors
Corporate Governance Reports
Articles of Association

Meet the Board of Directors

Chairman

Mats Blom

BA, Business Administration and Economics, University of Lund and MBA, IESE University of Navarra, Barcelona.

Chairman since: May 2024

Member of the Board since: April 2021

Number of shares in Egetis: 3,499,762

Number of share awards in Egetis: 187,853

Born: 1965

Other assignments: Board member of Hansa Biopharma AB and Pephexia Therapeutics ApS. Board member and Chair of the Audit Committee of Avacta Therapeutics.

Previous experience: CFO of Zealand Pharma A/B, a biotechnology company, at that time dual listed at Nasdaq in New York and Copenhagen. Mats Blom has also served as CFO at Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009, Northsea Therapeutics, Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also held roles as a management consultant at Gemini Consulting and Ernst & Young.

Independent in relation to the Company’s major shareholders and the Company and its management.

Board Member

Gunilla Osswald

Pharmacist and PhD in biopharmacy and pharmacokinetics at Uppsala University, Sweden

Member of the Board since: 2017

Number of shares in Egetis: 40,000

Number of share awards in Egetis: 125,235

Born: 1961

Other current assignments: President and Chief Executive Officer of BioArctic AB

Previous appointments: Board member of SP Process Development AB and SpineMedical Sverige AB

Independent in relation to the Company’s major shareholders and the Company and its management.

Board Member

Behshad Sheldon

Kandidatexamen i neurovetenskap från University of Rochester

Styrelseledamot sedan: 2023

Antal aktier i Egetis: 0

Antal aktierätter i Egetis: 125 235

Född: 1963

Övriga nuvarande uppdrag: Styrelseledamot, Camurus AB, styrelseordförande i FORCE (Female Opioid Research and Clinical Experts) i Princeton, New Jersey, styrelseledamot, Maxona Pharmaceuticals, Philadelphia, Pennsylvania och EVP & Managing Director, Biotech Value Advisors.

Tidigare utnämningar: President & CEO för Braeburn Pharmaceuticals fram till 2017. Hon har också omfattande global och amerikansk erfarenhet från olika ledande befattningar inom internationella läkemedelsföretag, däribland Smithkline Beecham, Bristol-Myers Squibb och Otsuka Pharmaceuticals.

Oberoende i förhållande till bolagets större aktieägare samt bolaget och dess ledning.

Board Member

Margarida Duarte

BS in Pharmaceutical Sciences from Universidade de Lisboa and an Executive Master’s degree in Medical Marketing Management from Instituto Universitário de Lisboa.

Member of the Board since: 2025

Number of shares in Egetis: 0

Number of share awards in Egetis: 162,774

Born: 1976

Other current assignments: Senior Vice President, GM Europe & Emerging Markets, Genmab.

Previous appointments: Vice President, Head of Commercial Canada, Europe and Middle East and Africa for Alnylam Pharmaceuticals until 2021, launching Alnylam’s first products in rare disease. Ms. Duarte also has extensive global experience from various senior commercial positions in international pharmaceutical companies, including STEPSTONE Pharma, Exelixis, Onyx Pharmaceuticals and Amgen, with a focus in oncology and hematology and rare diseases.

Independent in relation to the Company’s major shareholders and the Company and its management.

Board Member

Jay Donovan Wu

MBA from the Stanford Graduate School of Business and BSEc in Finance and BA in Neurobiology from the University of Pennsylvania.

Member of the Board since: 2026

Number of shares in Egetis: 0

Number of share awards in Egetis: 75,235

Born: 1985

Other current assignments: Executive Vice President and President, Ascendis US where he oversees the US organization.

Previous appointments: Wu spent 2012–2025 at Genentech, with multiple leading positions, of which Vice President and Head of Rare Diseases as his latest. Before Genentech, Wu worked at Bain & Company focused on Healthcare and Private Equity.

Independent in relation to the Company’s major shareholders and the Company and its management.

Board Member

Birgitte Volck

Medical Doctor and Ph.D. in arthritis, both from Copenhagen University, Denmark.

Member of the Board since: 2026

Number of shares in Egetis: 0

Number of share awards in Egetis: 75,235

Born: 1962

Other current assignments: Strategic Advisor, OMass Therapeutics, Non Executive Director and chair, Nominating and Corporate Governance Committee Soleno Therapeutics and Consultant at BIVO.

Previous appointments: She has held senior research and development leadership roles in several global companies. Her latest operating role was at Ascendis Pharma during 2021–2023 as Executive Vice President & Interim Chief Medical Officer. Prior to Ascendis Pharma she served as President R&D at Avrobio Inc from 2018–2020. At GSK, 2016–2018, she was Senior Vice President Head of R&D, Rare Diseases. At SOBI, 2012–2016, she was CMO and SVP Development. From 2000 to 2012 she served in executive roles of increasing responsibility at Amgen, Genzyme and Pharmexa. Since 2016 Dr. Volck has served on a number of publicly listed biotechnology boards such as Wilson Therapeutics AB during 2017–2018 until the company was acquired by Alexion for USD 850 million.

Independent in relation to the Company’s major shareholders and the Company and its management.

Leadership Team

Explore